USANew treatments and approvals
Fitusiran approved in the USA for hemophilia A and B
A decision by a medicines regulator (FDA, European Commission, etc.). The regulator has reviewed the clinical studies behind the drug. For accelerated or conditional approvals, the lasting benefit is still being confirmed.
The FDA has approved fitusiran to prevent bleeding in patients with hemophilia A or B. The approval covers patients aged 12 years and older. It can be used with or without factor inhibitors. The drug is an RNA therapy. It lowers the level of antithrombin, which acts as a brake on clotting. It can be injected under the skin at least six times a year. Serious side effects include blood clots, gallbladder problems and liver damage.
What does it mean for patients and families?
It offers a preventive treatment option with infrequent injections. But it requires close monitoring. Availability in Türkiye depends on TİTCK (Turkish Medicines and Medical Devices Agency) and SGK (Social Security Institution) processes.
Source
The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).
This page is translated from the Turkish original.
Related disease: Hemophilia (A and B)
This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.